ANTHEM BIOSCIENCES Financial Statement Analysis
|
||
|
The Revenues of ANTHEM BIOSCIENCES have increased by 15.17% YoY .
The Earnings Per Share (EPS) of ANTHEM BIOSCIENCES has increased by 30.61 % YoY. |
||
ANTHEM BIOSCIENCES Last 5 Annual Financial Results
[BOM: 544449|NSE : ANTHEM]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹2,124 Cr | ₹1,845 Cr | ₹1,419 Cr | ₹1,057 Cr | ₹1,231 Cr |
| Expenses | ₹1,290 Cr | ₹1,174 Cr | ₹914 Cr | ₹634 Cr | ₹664 Cr |
| Operating Profit (Excl OI) | ₹834 Cr | ₹671 Cr | ₹505 Cr | ₹423 Cr | ₹567 Cr |
| Other Income | ₹156 Cr | ₹86 Cr | ₹64 Cr | ₹85 Cr | ₹49 Cr |
| Interest | ₹7.06 Cr | ₹11 Cr | ₹9.66 Cr | ₹8.72 Cr | ₹12 Cr |
| Depreciation | ₹134 Cr | ₹89 Cr | ₹82 Cr | ₹64 Cr | ₹58 Cr |
| Profit Before Tax | ₹824 Cr | ₹657 Cr | ₹477 Cr | ₹497 Cr | ₹546 Cr |
| Profit After Tax | ₹592 Cr | ₹451 Cr | ₹367 Cr | ₹385 Cr | ₹406 Cr |
| Consolidated Net Profit | ₹592 Cr | ₹451 Cr | ₹367 Cr | ₹385 Cr | ₹406 Cr |
| Earnings Per Share (Rs) | ₹10.54 | ₹8.07 | ₹6.57 | ₹6.75 | ₹462.10 |
| PAT Margin (%) | 27.11 | 24.38 | 25.88 | 36.44 | 32.94 |
| ROE(%) | 21.98 | 20.99 | 20.04 | 24.89 | 39.44 |
| ROCE(%) | 29.62 | 28.55 | 24.21 | 31.08 | 50.94 |
| Total Debt/Equity(x) | 0.02 | 0.05 | 0.12 | 0.07 | 0.03 |
Key Financials |
||
| Market Cap | : | ₹ 44,517.1 Cr |
| Revenue (TTM) | : | ₹ 2,002.3 Cr |
| Net Profit(TTM) | : | ₹ 575.9 Cr |
| EPS (TTM) | : | ₹ 10.2 |
| P/E (TTM) | : | 77.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ANTHEM BIOSCIENCES | -0.2% | 3.8% | NA |
| SUN PHARMACEUTICAL INDUSTRIES | 0.6% | 6% | 14.6% |
| DIVIS LABORATORIES | 1.2% | 10.5% | 7.7% |
| TORRENT PHARMACEUTICALS | -0.4% | 11% | 40.8% |
| CIPLA | -1.6% | -2.1% | -4.8% |
| DR REDDYS LABORATORIES | -4.6% | -14.8% | -8.4% |
| MANKIND PHARMA | -1% | 3.7% | -5.6% |
| LUPIN | -4.2% | 2.9% | 22.7% |
| ZYDUS LIFESCIENCES | -3.1% | 0.6% | 13.7% |
ANTHEM BIOSCIENCES Revenues
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 15.17 % |
| 5 Yr CAGR | 14.61 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹2,124 Cr | 15.17 | |
| Mar2025 | ₹1,845 Cr | 29.96 | |
| Mar2024 | ₹1,419 Cr | 34.29 | |
| Mar2023 | ₹1,057 Cr | -14.16 | |
| Mar2022 | ₹1,231 Cr | - | |
ANTHEM BIOSCIENCES Operating Profit
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 24.28 % |
| 5 Yr CAGR | 10.12 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹834 Cr | 24.28 | |
| Mar2025 | ₹671 Cr | 32.85 | |
| Mar2024 | ₹505 Cr | 19.45 | |
| Mar2023 | ₹423 Cr | -25.43 | |
| Mar2022 | ₹567 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 7.92 % |
| 5 Yr CAGR | -3.91 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 39.26% | 7.92 | |
| Mar2025 | 36.38% | 2.22 | |
| Mar2024 | 35.59% | -11.05 | |
| Mar2023 | 40.01% | -13.14 | |
| Mar2022 | 46.06% | - | |
ANTHEM BIOSCIENCES Profit After Tax
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 31.14 % |
| 5 Yr CAGR | 9.91 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹592 Cr | 31.14 | |
| Mar2025 | ₹451 Cr | 22.86 | |
| Mar2024 | ₹367 Cr | -4.64 | |
| Mar2023 | ₹385 Cr | -5.02 | |
| Mar2022 | ₹406 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 11.20 % |
| 5 Yr CAGR | -4.75 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 27.11 % | 11.20 | |
| Mar2025 | 24.38 % | -5.80 | |
| Mar2024 | 25.88 % | -28.98 | |
| Mar2023 | 36.44 % | 10.63 | |
| Mar2022 | 32.94 % | - | |
ANTHEM BIOSCIENCES Earnings Per Share (EPS)
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 30.61 % |
| 5 Yr CAGR | -61.14 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹11 | 30.61 | |
| Mar2025 | ₹8.07 | 22.83 | |
| Mar2024 | ₹6.57 | -2.67 | |
| Mar2023 | ₹6.75 | -98.54 | |
| Mar2022 | ₹462 | - | |
ANTHEM BIOSCIENCES Return on Capital Employed (ROCE)
[BOM: 544449|NSE : ANTHEM]
| Y-o-Y | 3.75 % |
| 5 Yr CAGR | -12.68 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 29.62% | 3.75 | |
| Mar2025 | 28.55% | 17.93 | |
| Mar2024 | 24.21% | -22.10 | |
| Mar2023 | 31.08% | -38.99 | |
| Mar2022 | 50.94% | - | |
ANTHEM BIOSCIENCES Share Price vs Sensex
| Current Share Price | : | ₹790.2 |
| Current MarketCap | : | ₹ 44,517.1 Cr |
| Updated EOD on | : | Jul 27,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ANTHEM BIOSCIENCES | -0.2% |
3.8% |
|
| SENSEX | -1.1% |
-0.2% |
-6.6% |
ANTHEM BIOSCIENCES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE IPO | 0.5% | 0.4% | 11.3% |
| BSE HEALTHCARE | -0.3% | 3.3% | 10.5% |
| BSE 1000 | -0.8% | 0.2% | -1.2% |
| BSE 500 | -0.8% | 0.2% | -1.5% |
| BSE 400 MIDSMALLCAP INDEX | -1% | 0.4% | 1.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY IPO INDEX | 0.1% | 1.1% | 8.2% |
| NIFTY INDIA MANUFACTURING | 0.1% | 0.8% | 10.4% |
| NIFTY500 HEALTHCARE INDEX | -0.3% | 3.3% | 10.2% |
| NIFTY MIDCAP 150 | -0.7% | 0.3% | 4.2% |
| NIFTY LARGEMIDCAP 250 | -0.7% | 0.2% | 0.8% |
You may also like the below Video Courses
FAQ about ANTHEM BIOSCIENCES Financials
How the annual revenues of ANTHEM BIOSCIENCES have changed ?
The Revenues of ANTHEM BIOSCIENCES have increased by 15.17% YoY .
How the Earnings per Share (EPS) of ANTHEM BIOSCIENCES have changed?
The Earnings Per Share (EPS) of ANTHEM BIOSCIENCES has increased by 30.61 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs